Danielle Mercatante Carrick, Ph.D., M.H.S.
Program Director, Genomic Epidemiology Branch

Address:
Epidemiology and Genomics Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
National Institutes of Health
9609 Medical Center Drive, Rm. 4E224, MSC 9763
Bethesda, MD 20892
(For express delivery, use Rockville, MD 20850)

Interest Areas

  • Immunology, infectious diseases, and autoimmune diseases associated with cancer risk
  • Pharmacoepidemiology and pharmacogenomics
  • Biospecimen research
  • Functional genomics

Degrees

  • Ph.D. - Pharmacology
    University of North Carolina at Chapel Hill
  • M.H.S. - Clinical Research
    Duke University
  • B.S. - Biology
    University of Richmond

Biography

Dr. Danielle Mercatante Carrick is a Program Director in the Genomic Epidemiology Branch (GEB)—formerly the Host Susceptibility Factors Branch (HSFB)—of the Epidemiology and Genomics Research Program (EGRP) in NCI's Division of Cancer Control and Population Sciences (DCCPS). She is responsible for managing a research grant portfolio related to genetic and immunologic factors that influence personal susceptibility to cancer, including inflammation. She is the DCCPS biospecimen coordinator, the lead contact for NCI's Provocative Question #3, and the DCCPS contact for the IMAT program.

Dr. Carrick is a molecular pharmacologist and clinical researcher, with experience conducting epidemiological, biomedical, genetic, and pharmacological research studies focused on cancer, biospecimen science, autoimmune diseases, infectious diseases, immunology, and transfusion medicine. Prior to joining EGRP, she served as Co-Deputy Project Director and Biospecimen Lead for the NCI's Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial and as an Epidemiologist for the National Heart, Lung, and Blood Institute's Retrovirus Epidemiology Donor Study II (REDS-II) at Westat, Inc.

Dr. Carrick completed her postdoctoral training as an Intramural Research Training Award (IRTA) Fellow in the Office of Clinical Research at the National Institute of Environmental Health Sciences (NIEHS). She conducted studies to examine potential genetic associations with cancer, autoimmune disorders, asthma, and congenital hydrocephalus; and to develop laboratory tests that measured immune regulator gene expression levels in whole blood and monocytes in response to environmental factors. While at NIEHS, Dr. Carrick was selected to receive training in epidemiology through the NIH-Duke Training Program in Clinical Research.

Publications

Piehowski PD, Petyuk VA, Sontag RL, Gritsenko MA, Weitz KK, Fillmore TL, Moon J, Makhlouf H, Chuaqui RF, Boja ES, Rodriguez H, Lee JSH, Smith RD, Carrick DM, Liu T, Rodland KD. Residual tissue repositories as a resource for population-based cancer proteomic studiesExternal Web Site Policy. Clinical Proteomics. [Epub ahead of print]

Liu CH, Abrams ND, Carrick DM, Chander P, Dwyer J, Hamlet MRJ, Macchiarini F, PrabhuDas M, Shen GL, Tandon P, Vedamony MM. Biomarkers of chronic inflammation in disease development and prevention: challenges and opportunities. Nat Immunol. 2017 Oct 18;18(11):1175-1180.

Zhu CS, Huang WY, Pinsky PF, Berg CD, Sherman M, Yu KJ, Carrick DM, Black A, Hoover R, Lenz P, Williams C, Hawkins L, Chaloux M, Yurgalevitch S, Mathew S, Miller A, Olivo V, Khan A, Pretzel SM, Multerer D, Beckmann P, Broski KG, Freedman ND. The Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial Pathology Tissue Resource. Cancer Epidemiol Biomarkers Prev. 2016 Dec;25(12):1635-1642.

Carrick DM, Black A, Gohagan JK, Khan A, Pettit K, Williams C, Yu K, Yurgalevitch S, Huang WY, Zhu C. The PLCO Biorepository: creating, maintaining, and administering a unique biospecimen resource. Rev Recent Clin Trials. 2015;10(3):212-22.

Carrick DM, Mehaffey MG, Sachs MC, Altekruse S, Camalier C, Chuaqui R, Cozen W, Das B, Hernandez BY, Lih CJ, Lynch CF, Makhlouf H, McGregor P, McShane LM, Phillips Rohan J, Walsh WD, Williams PM, Gillanders EM, Mechanic LE, Schully SD. Robustness of Next Generation Sequencing on older formalin-fixed paraffin-embedded tissue. PLoS One. 2015 Jul 29;10(7):e0127353.

Carrick DM, Chaturvedi AK, Shiels MS, Divi RL, Filipski KK, Hebert EF, Verma M, Hildesheim A. Using immune marker panels to evaluate the role of inflammation in cancer: summary of an NCI-sponsored workshop. Cancer Epidemiol Biomarkers Prev. 2015 June 24.

Schully SD, Carrick DM, Mechanic LE, Srivastava S, Anderson GL, Baron JA, Berg CD, Cullen J, Diamandis EP, Doria-Rose VP, Goddard KA, Hankinson SE, Kushi LH, Larson EB, McShane LM, Schilsky RL, Shak S, Skates SJ, Urban N, Kramer BS, Khoury MJ, Ransohoff DF. Leveraging biospecimen resources for discovery or validation of markers for early cancer detection. J Natl Cancer Inst. 2015 Feb 16;107(4).

Carrick DM, Mette E, Hoyle B, Rogers SD, Gillanders EM, Schully SD, Mechanic LE. The use of biospecimens in population-based research: a review of the National Cancer Institute's Division of Cancer Control and Population Sciences grant portfolio. Biopreserv Biobank. 2014 Aug;12(4):240-5.

Altekruse SF, Rosenfeld GE, Carrick DM, Pressman EJ, Schully SD, Mechanic LE, Cronin KA, Hernandez BY, Lynch CF, Cozen W, Khoury MJ, Penberthy LT. SEER cancer registry biospecimen research: yesterday and tomorrow. Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2681-7.

Delwart E, Slikas E, Stramer SL, Kamel H, Kessler D, Krysztof D, Tobler LH, Carrick DM, Steele W, Todd D, Wright DJ, Kleinman SH, Busch MP; NHLBI-REDS-II Study Group. Genetic diversity of recently acquired and prevalent HIV, hepatitis B virus, and hepatitis C virus infections in US blood donors. J Infect Dis. 2012 Mar 15;205(6):875-85.

Carrick DM, Norris PJ, Endres RO, Pandey S, Kleinman SH, Wright D, Sun Y, Busch MP; National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study-II. Establishing assay cutoffs for HLA antibody screening of apheresis donors. Transfusion. 2011 Oct;51(10):2092-101.

Carrick DM, Blackshear PJ. Comparative expression of tristetraprolin (TTP) family member transcripts in normal human tissues and cancer cell lines. Arch Biochem Biophys. 2007 Jun 15;462(2):278-85.

Carrick DM, Chulada P, Donn R, Fabris M, McNicholl J, Whitworth W, Blackshear PJ. Genetic variations in ZFP36 and their possible relationship to autoimmune diseases. J Autoimmun. 2006 May;26(3):182-96.

Return to Top